Shareholders approve key resolutions at the 2026 Annual General Shareholders’ Meeting

Barcelona, Spain, June 18, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, announced that its shareholders approved the main resolutions submitted for vote at the 2026 Annual General Shareholders’ Meeting, held today at the company’s headquarters in Sant Cugat del Vallès, Barcelona.

Shareholders endorsed the key proposals presented by the Board of Directors, including approval of the parent company and consolidated annual financial statements, the non-financial and sustainability reporting statement, and the Board’s management of the company during the fiscal year.

Shareholders also approved:

• The re-election of Montserrat Muñoz Abellana and Susana González Rodríguez as members of the Board of Directors;
• the reappointment of Deloitte Auditores, S.L. as the independent auditor of the Company and its consolidated group for fiscal years 2027, 2028, and 2029;
• amendments to the Company’s Directors’ Remuneration Policy;
• the Annual Directors’ Remuneration Report, on an advisory basis; and
• a reduction of the Company’s share capital, up to a maximum amount representing 10% of the share capital as of the date of the resolution, through the cancellation of treasury Class A and Class B shares.

Shareholders also expressed support for Grifols’ strategy to further strengthen its financial position, drive profitable business growth, and continue advancing its operational and innovation priorities.

A total of 579 shareholders attended or were represented at the Annual General Shareholders’ Meeting for fiscal year 2025, representing 261,093,456 shares and 61.27% of the Company’s voting share capital.

During the meeting, Grifols presented its 2025 financial results. The company reported revenue of €7,524 million, up 7% year-over-year, and more than doubled net profit to €402 million. Adjusted EBITDA reached €1,825 million, while free cash flow totaled €468 million, driven by EBITDA growth, working capital management, normalized capital expenditures, and lower financing costs.

Anne-Catherine Berner, Non-Executive Chairwoman of Grifols, highlighted the importance of maintaining a long-term perspective in the company’s development: “We are evaluating opportunities to unlock the value of Grifols’ exceptional assets and enhance our financial flexibility, while preserving the company’s long-term strength and growth potential”.

Raimon Grifols, Vice Chairman of the Board of Directors, emphasized shareholders’ confidence in the company’s future: “For more than a century, Grifols has grown guided by a long-term vision, a strong commitment to innovation, and a clear dedication to serving patients. Today, we continue to move forward to strengthen the company and contribute to a more resilient, balanced, and sustainable global plasma supply model that addresses the growing needs of patients and healthcare systems worldwide. On behalf of the Board of Directors, I would like to thank our shareholders for their continued trust in Grifols. Their support motivates us to keep preparing the company to lead the future of an industry that is essential to global health.”

Commitment to Sustainability and Corporate Governance

The Annual General Shareholders’ Meeting also endorsed Grifols’ performance in sustainability and corporate governance through approval of the Company’s 2025 Non-Financial Information and Sustainability Statement.

Grifols remains committed to responsible and transparent management aligned with the highest international standards of corporate governance, business ethics, and sustainability, while continuing to advance the goals set forth in its Grifols Agenda 2030.

For more information: Grifols 2026 Annual General Shareholders’ Meeting and 2025 Integrated Annual and Sustainability Report.